Phagocytosing Neutrophils Produce and Release High Amounts of the Neutrophil-activating Peptide 1/Interleukin 8

By Flavia Bazzoni, Marco A. Cassatella, Filippo Rossi, Miroslav Ceska,* Beatrice Dewald,‡ and Marco Baggiolini‡

From the Institute of General Pathology, University of Verona, I-37134 Verona, Italy, the *Sandoz Research Institute Inc., A-1235 Vienna, Austria, and the ‡Theodor-Kocher Institute, University of Bern, CH-3000 Bern 9, Switzerland

Summary

After phagocytosis of yeast opsonized with IgG, neutrophil leukocytes (polymorphonuclear leukocytes [PMN]) expressed high levels of neutrophil-activating peptide 1/interleukin 8 (NAP-1/IL-8) mRNA, which peaked after 3–5 h and were still elevated after 18 h. A similar but quantitatively less prominent effect was obtained with lipopolysaccharide (LPS). After phagocytosis, but not after exposure to LPS, the PMN progressively released considerable amounts of NAP-1/IL-8 into the culture medium (18.6–50 ng/ml in 18 h). The peptide released was biologically active, as indicated by the transient elevation of cytosolic-free calcium in PMN exposed to aliquots of the culture supernatants, and desensitization by prestimulation of the cells with recombinant NAP-1/IL-8. By producing NAP-1/IL-8 at sites where they phagocytose invading microorganisms, PMN could enhance the recruitment of new defense cells.

Materials and Methods

Cell Purification and Culture. PMN were isolated by two consecutive Ficoll-Hypaque density gradient centrifugations to minimize contamination with monocytes (10). Monocytes were purified from the PBMC by adherence to plastic for 1 h (10). As assessed by Wright staining and unspecific esterase cytochemistry PMN preparations contained <1% monocytes, and the purity of the monocyte preparations was on average 90%. PMN (10⁶/ml) and monocytes (1–2 x 10⁶/ml) were cultured in polystyrene flasks (37°C, 5% CO₂) for up to 18 h in RPMI 1640 containing antibiotics and 10% FCS. The cells were stimulated at time zero with heat-killed yeast opsonized with IgG (YIgG; particle/cell ratio of 2:1), or Escherichia coli LPS (1 μg/ml). Cell viability after 18 h in culture was >98% for both PMN and monocytes as assessed by trypan blue exclusion. All solutions were prepared with endotoxin-free water for clinical use (10).

RNA Isolation and Northern Blot Analysis. Total RNA was purified from samples of 8 x 10⁷ PMN or 5 x 10⁶ monocytes by the guanidinium isothiocyanate/cesium chloride method (12), size separated by agarose gel electrophoresis, blotted onto a nylon membrane (Schleicher & Schuell, Inc., Keene, NH), and hybridized with a radiolabeled 0.7-kb EcoRI fragment prepared from a cDNA for human NAP-1/IL-8 kindly provided by Dr. I. Lindley (13). RNA loading of the gels was assessed with phosphoglycerate kinase (PGK) or β-actin cDNA. Several exposures of each autoradiograph were quantified by laser densitometry (ultrascan XS; LKB Instruments, Inc., Gaithersburg, MD) to ensure that the measurements were within a linear range of signal intensity.
**NAP-1/IL-8 Assay.** NAP-1/IL-8 was determined using a double-ligand ELISA method in cell-free supernatants of PMN or monocyte cultures stored at -70°C. Samples and recombinant NAP-1/IL-8 standards (0.02-10 ng/ml) (13) were incubated for 2 h at 37°C in microtiter plates coated with a mouse anti-NAP-1/IL-8 mAb. After washing, a goat anti-NAP-1/IL-8 mAb conjugated to alkaline phosphatase was added, and finally, the activity was determined with p-nitrophenylphosphate.

**Cytosolic-free Ca²⁺ Measurements.** Neutrophils were loaded with Fura-2 for 20 min at 37°C (0.2 nmol Fura-2-AM/10⁶ cells), washed, and resuspended in a buffer containing 136 mM NaCl, 4.8 mM KCl, 1 mM CaCl₂, 5 mM glucose, and 20 mM Hepes, adjusted to pH 7.4. [Ca²⁺]i changes were induced by addition of 10-50-µl samples of the culture supernatants or standard solutions of recombinant NAP-1/IL-8 or fMet-Leu-Phe, and monitored as described (14).

**Results**

PMN were exposed to YIgG or LPS, and the production of NAP-1/IL-8 was studied after different periods of time. When PMN were cultured in the presence of YIgG, phagocytosis proceeded rapidly, and after 45 min, the phagocytic index was 117 ± 13 (number of particles per 100 PMN; mean ± SD of three experiments performed with PMN from different donors). The expression of NAP-1/IL-8 mRNA in such cells is shown by the Northern blot analysis presented in Fig. 1. Phagocytosis of YIgG induced a significant, time-dependent increase in the level of the specific mRNA, which was already evident 1 h after addition of the particles. The levels reached a maximum after 3-5 h and were still elevated after 18 h. A similar time course of NAP-1/IL-8 mRNA enhancement was observed when the cells were exposed to 1 µg/ml LPS (data not shown). In most experiments, control PMN expressed small amounts of NAP-1/IL-8 mRNA. Since monocytes are the main producers of NAP-1/IL-8 mRNA, expression of NAP-1/IL-8 was studied in human PMN and monocyes in control medium and after phagocytosis of opsonized yeast (YIgG) or exposure to LPS. mRNA was prepared after 6 h of culture, and Northern blot analysis was performed under identical conditions for PMN and monocytes. 6 µg of total RNA was loaded on each lane. Densitometric evaluation (right) is as in Fig. 1. PMN and monocytes were prepared from the same donor. Similar results were obtained in two additional experiments.

![Figure 1.](image1)

**Figure 1.** NAP-1/IL-8 mRNA expression in human PMN after phagocytosis of opsonized yeast (YIgG). PMN were cultured for up to 18 h in the presence (+) or absence (−) of YIgG, and mRNA was prepared at different times. *(Top)* Northern blots; 5 µg of total RNA was loaded on each lane. *(Bottom)* Densitometry of the autoradiographs (filled columns, controls; open columns, YIgG). The values were normalized on the basis of hybridization to actin mRNA. Data are representative for three experiments performed under the same conditions with different neutrophil preparations.

![Figure 2.](image2)

**Figure 2.** NAP-1/IL-8 mRNA expression in human PMN and monocytes in control medium and after phagocytosis of opsonized yeast (YIgG) or exposure to LPS. mRNA was prepared after 6 h of culture, and Northern blot analysis was performed under identical conditions for PMN and monocytes. 6 µg of total RNA was loaded on each lane. Densitometric evaluation (right) is as in Fig. 1. PMN and monocytes were prepared from the same donor. Similar results were obtained in two additional experiments.

![Figure 3.](image3)

**Figure 3.** NAP-1/IL-8 release by human PMN cultured for up to 18 h in control medium (O) or in the presence of YIgG (●) or LPS (■). Data from three different PMN preparations exposed to YIgG are shown together with data from one preparation exposed to LPS or medium alone.
(2, 3), mRNA expression was compared in PMN and monocytes purified from the same donor and stimulated with Y-IgG or LPS under identical conditions. The results of a representative experiment are shown in Fig. 2. In both types of phagocytes, NAP-1/IL-8 mRNA transcripts were already detected under control conditions and the expression was greatly enhanced in response to either stimulus. As revealed by the densitometric evaluation corrected on the basis of actin mRNA expression, PMN and monocytes responded to similar extents to Y-IgG. The effect of LPS, by contrast, was markedly lower in PMN than in monocytes. Expression in PMN challenged with yeast particles was not altered by polymyxin B (5 μg/ml), indicating that the enhancement was due to phagocytosis and not to contamination with LPS (data not shown).

In subsequent experiments, we determined whether NAP-1/IL-8 mRNA was translated and the peptide secreted. As shown in Fig. 3, PMN stimulated with Y-IgG progressively released considerable amounts of immunoreactive NAP-1/IL-8 into the culture medium, reaching concentrations of 18.6-50 ng/ml in 18 h (34.3 ± 14.9, mean ± SD, n = 4). By contrast, NAP-1/IL-8 release by PMN exposed to LPS for the same period was 0.6 ± 0.4 ng/ml (n = 3), and thus exceeded only slightly the values observed in control cultures (0.08-0.2 ng/ml). The release of NAP-1/IL-8 in monocyte cultures was considerably higher; on a per cell basis, monocytes stimulated with either LPS or Y-IgG produced 30-40-fold more NAP-1/IL-8 than Y-IgG-stimulated PMN. The marked difference in the production of NAP-1/IL-8 by PMN challenges with Y-IgG and LPS indicates that the NAP-1/IL-8 recovered in the cultures was not due to production by contaminating monocytes, which responded equally well to either stimulus.

The biological activity of NAP-1/IL-8 in the culture supernatants of PMN that had phagocytosed Y-IgG was assessed by measuring [Ca^{2+}]_{i} changes in PMN suspensions after loading with Fura-2. Supernatant samples induced a rapid and transient rise in [Ca^{2+}]_{i} that was qualitatively similar to that observed with recombinant NAP-1/IL-8 or FMet-Leu-Phe. In addition, the [Ca^{2+}]_{i} changes elicited by the supernatants were prevented or markedly attenuated by prestimulation (and desensitization) of the PMN with recombinant NAP-1/IL-8. For desensitization, recombinant NAP-1/IL-8 was added to the cells 1 min before the supernatant sample to be tested.

**Discussion**

This study shows that circulating, mature human neutrophils are capable of producing and releasing considerable amounts of NAP-1/IL-8. The induction of NAP-1/IL-8 mRNA was observed upon exposure of the cells to stimuli that they commonly encounter at sites of infection, endotoxin and opsonized particles, while the release of the NAP was largely restricted to PMN that had phagocytosed.

Since mononuclear phagocytes produce large amounts of NAP-1/IL-8 (2), it was important to exclude that monocyte contamination could account for the release of the peptide attributed to PMN. Multiple evidence argues against this possibility. (a) The purity of the PMN preparations used was at least 99%. (b) Northern blot analysis of equal amounts of total RNA extracted from PMN and monocyte preparations stimulated with Y-IgG yielded NAP1/IL-8 mRNA bands of similar intensity (Fig. 2), indicating that expression occurred in both cells. (c) Total release of NAP-1/IL-8 in PMN cultures was 100-200-fold higher after Y-IgG phagocytosis than after exposure to LPS (Fig. 3), whereas in monocytes the release was similar with both stimuli. Additional evidence for the purity of the PMN population used stems from parallel studies of the expression of IL-6 mRNA, which was readily detectable in monocyte but not in PMN preparations (9a).

PMN have long been known to generate bioactive lipids, such as LTB4 and PAF, that act as chemotactic agonists, and may function as amplifiers of the defense response (6, 7). LTB4 and PAF are generated within seconds to minutes of stimulation, and are, therefore, early acting agents. The present demonstration of production and release of NAP-1/IL-8 after phagocytosis confers more strength to the notion that PMN have the ability to enhance antimicrobial defense by recruiting new cells. In contrast to the lipid agonists, which are short lived, NAP-1/IL-8 is known to persist in active form for long periods in the tissues (2), and its action is thus likely to be protracted.

We thank Federica Calzetti and Andrea Blaser for excellent technical assistance.

This work was supported by grants from the Comitato Nazionale Biotecnologie e Biologia Molecolare (90.01260.CT14), and Target Project on Biotechnology and Bioinstrumentation (90.00053.70) and by a generous contribution of the Italian Association for Cancer Research to F. Rossi. Grant 31-25700.88 of the Swiss National Science Foundation supported in part the work of B. Dewald and M. Baggiolini.

Address correspondence to Marco A. Cassatella, Institute for General Pathology, University of Verona, Strada Le Grazie 4, I-37134 Verona, Italy.

Received for publication 4 December 1990.

We thank Federica Calzetti and Andrea Blaser for excellent technical assistance.

This work was supported by grants from the Comitato Nazionale Biotecnologie e Biologia Molecolare (90.01260.CT14), and Target Project on Biotechnology and Bioinstrumentation (90.00053.70) and by a generous contribution of the Italian Association for Cancer Research to F. Rossi. Grant 31-25700.88 of the Swiss National Science Foundation supported in part the work of B. Dewald and M. Baggiolini.

Address correspondence to Marco A. Cassatella, Institute for General Pathology, University of Verona, Strada Le Grazie 4, I-37134 Verona, Italy.

Received for publication 4 December 1990.
References


